SUGAR LAND, TX -- (Marketwire) -- 03/09/12 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- It is lonely at the top, when considering North America in terms of Pharmaceutical-Biotech capital and maintenance (MRO) investment. Out of $2.7 billion in scheduled North American Pharma-Bio project starts for the first quarter of 2012, New England jumped to the top of the heap by claiming more than $1 billion of the total for only nine projects, out of a total of 106. The region can thank Massachusetts for putting it there.
Massachusetts has long been the darling of the industry, thanks to a blend of superior infrastructure and a vast amount of intellectual capital. The state currently has the single-largest 2012 launch project reported thus far: Swiss drug giant Novartis AG's (NYSE:NVS) (Basel, Switzerland) plan for a $600 million expansion of its Institutes for Biomedical Research division in Cambridge.
For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showAbstract.jsp?newsitemID=203670&refer=marketwire, or browse other breaking industrial news stories at www.industrialinfo.com.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, and eight offices outside of North America, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the www.industrialinfo.com "Contact Us" page.